IMGN is run by scientists, got suckered and is in bed with Roche as have many other biotechs. IMGN clearly has the best ADC and had not monetized its value beyond cancer but its current "overvaluation" is a sign of good times to come after the secondary and people with business expertise are brought are board.
What a scourge of our lifetime taking 40-year old cousins, mothers, daughters, aunts..typically discovered when too late. ...a deadly nasty cancer. So glad this drug appears to be a game changer. Hang on gals and seek out compassionate use with the manufacturer and FDA.